> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Says Zepatier Tops Sovaldi Combo
- URL: https://www.fdaweb.com/merck-says-zepatier-tops-sovaldi-combo/
- Published: 2016-04-14T12:00:00.000Z
- Updated: 2026-09-14T20:54:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135366

> Merck says that the C-EDGE comparative Phase 3 study of Zepatier (elbasvir and grazoprevir) versus a regimen of Gilead’s Sovaldi (sofosbuvir) plus peginterferon and ribavirin showed Zepatier superiority in treatment-experienced patients with chronic hepatitis C genotype 1 or 4 infection. FDA approved the drug 1/28 based in part on prior studies from the Phase 3 program.  
>  
> The company describes Zepatier as a fixed-dose combination product containing elbasvir, a hepatitis C virus NS5A inhibitor, and grazoprevir, a hepatitis C virus NS3/4A protease inhibitor. It is indicated with or without ribavirin for treating chronic hepatitis C virus genotype 1 or 4 infection in adults.